CTLA4 and neoplasm: By releasing immune “brakes” (ie, CTLA-4, PD-1/L1) that tumor cells co-opt to suppress T cells, ICBs rejuvenate tumor-infiltrating T cells (TILs),2-4 leading to tumor rejection.